Thursday, June 29 at 9:00 AM–10:30AM ET
Most of what we hear about regarding the HIV prevention pipeline is about long-acting, longer-acting, and even longer-acting products that deliver drug throughout the body and require a trained clinician to deliver. However, these attributes are not desirable to many folks, and communities want a range of choices. Researchers and advocates for years have been working on HIV prevention products specifically for the back door (rectum) to provide protection during anal intercourse. These products are user-controlled, non-systemic (the drug stays in the booty and only the booty), and are short-acting, so you don’t have to commit to having a prevention drug in your body for a year or longer. Join us for a dynamic discussion regarding the latest research on Booty PrEP – aka rectal microbicides – with our multi-talented panel.
Speakers include: Jonathan Baker, PA, “Rectal Rockstar”, Dr. Craig Hendrix, Johns Hopkins, Juan Michael Porter II, The Body, and Dr. Sharon Riddler, University of Pittsburgh
The Long-Acting Therapeutics Patents and Licenses Database (LAPaL)
The Long-Acting Therapeutics Patents and Licenses Database (LAPaL) is a free online database that provides information on long-acting therapeutics that could have impact in resource-constrained settings. It includes technical and intellectual property information on these technologies as well as an interactive visualisation tool to navigate the pipeline progress. Click here for a brief overview of…
A Randomized Trial of Safety, Acceptability and Adherence of Three Rectal Microbicide Placebo Formulations Among Young Sexual and Gender Minorities Who Engage in Receptive Anal Intercourse (MTN-035)
This journal article from PLOS ONE was a trial seeking to evaluate the safety, acceptability, and adherence to three placebo modalities (insert, suppository, enema) prior to receptive anal intercourse (RAI).
Incorporating End-users’ Voices into the Development of an Implant for HIV Prevention: A discrete choice experiment in South Africa and Zimbabwe
This article from BMC Women’s Health describes the results of a discrete choice experiment undertaken with adolescent girls and young women in South Africa and Zimbabwe where participants were asked their preferences for a hypothetical HIV prevention implant.
Long-acting HIV Pre-exposure Prophylaxis (PrEP) Approaches: Recent advances, emerging technologies, and development challenges
This review from Expert Opinion on Drug Delivery discusses the current state of the long acting PrEP field, recent advances, and emerging technologies, including ARV prodrug modifications and new drug delivery systems. Technological challenges, knowledge gaps, preclinical testing considerations, and future directions important in the context of clinical translation and implementation of long acting HIV…
End-user Research in Support of Long-acting Systemic Antiretroviral Delivery Systems: Insights from qualitative research with providers and target users in South Africa
This article from BMC Infectious Diseases describes qualitative research investigating perceptions of and preferences for a long-acting, biodegradable implantable PrEP product designed to address challenges relating to adhering to a daily pill regimen amongst adolescent girls and young women and sex workers in Guateng Province, South Africa.
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection
This article from JAIDS describes the results of a randomized, double-blind, placebo-controlled, phase 1 trial of a next-generation radiopaque islatravir-eluting implant to assess safety, tolerability, and pharmacokinetics.
More than Just Oral PrEP: Exploring interest in rectal douche, dissolvable implant, removable implant and injection HIV prevention approaches among racially diverse men who have sex with men in the Northeast Corridor
This exploratory and cross-sectional study investigated interest in four biomedical prevention tools—rectal douche, dissolvable implant, removable implant and injection—among a racially diverse sample of men who have sex with men from the Northeast Corridor region between Philadelphia and Trenton.
HIV Prevention Research and Development Database
The HIV Prevention Research & Development Database is a comprehensive source of information on biomedical HIV prevention clinical trials that are planned, ongoing or completed. The database allows users to view clinical trials around the world, gaining an understanding of the many developments currently being made in the field of HIV prevention research.
The Years Ahead in Biomedical HIV Prevention Research
This graphic shows the updated status of large-scale prevention trials through 2024.
The Future of ARV-Based Prevention and More
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.